- Trials with a EudraCT protocol (39)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
39 result(s) found for: Motor program.
Displaying page 1 of 2.
EudraCT Number: 2021-004424-15 | Sponsor Protocol Number: NOE-TTS-211 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Noema Pharma Australia Pty Ltd | |||||||||||||
Full Title: An open-label, Phase IIa, multi-center, 12-week prospective study to evaluate the safety and efficacy of NOE-105 at a daily dose range of 2.5mg to 15mg in adult and adolescent male patients with To... | |||||||||||||
Medical condition: Tourette Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004865-26 | Sponsor Protocol Number: M12-927 | Start Date*: 2015-08-27 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: An Open-label, Randomized 26-Week Study Comparing Levodopa-Carbidopa INteStInal Gel (LCIG) Therapy to Optimized Medical Treatment (OMT) on Non-Motor Symptoms (NMS) in Subjects with Advanced Parkins... | |||||||||||||
Medical condition: Non-motor symptoms in advanced Parkinson's disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) SE (Completed) IT (Completed) ES (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-004727-33 | Sponsor Protocol Number: CY5032 | Start Date*: 2022-10-28 | |||||||||||
Sponsor Name:Cytokinetics Inc | |||||||||||||
Full Title: A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031) | |||||||||||||
Medical condition: Amyotrophic Lateral Sclerosis (ALS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Prematurely Ended) BE (Completed) NL (Prematurely Ended) SE (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended) ES (Prematurely Ended) PT (Ongoing) DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001592-37 | Sponsor Protocol Number: F02695_LP_2_05 | Start Date*: 2012-10-16 | |||||||||||
Sponsor Name:Pierre Fabre Médicament; Represented by Institut de Recherche Pierre Fabre | |||||||||||||
Full Title: Effect of 3-month treatment with F2695 (75mg OD) on improving functional recovery of patients with ischemic stroke. A Multicenter, Randomised, Double-blind, Parallel-group, Placebo-Controlled Study. | |||||||||||||
Medical condition: Functionnal impairment after acute ischemic stroke | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) CZ (Completed) PT (Completed) HU (Completed) BE (Completed) IT (Completed) FR (Completed) SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-001329-26 | Sponsor Protocol Number: EPOSS2010 | Start Date*: 2011-08-03 | |||||||||||
Sponsor Name:ISTITUTO NEUROLOGICO "CARLO BESTA" | |||||||||||||
Full Title: ErythroPOietin in ALS: a Study of dose-finding and Safety | |||||||||||||
Medical condition: Amyotrophic Lateral Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003950-15 | Sponsor Protocol Number: rhLAMAN-10 | Start Date*: 2015-01-22 | |||||||||||
Sponsor Name:Zymenex A/S | |||||||||||||
Full Title: A single center, open label clinical trial investigating the long-term efficacy of rhLAMAN (recombinant human alpha-mannosidase or Lamazym) treatment in subjects with alpha-Mannosidosis who previo... | |||||||||||||
Medical condition: alpha-Mannosidosis | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012037-30 | Sponsor Protocol Number: SNT-III-003 | Start Date*: 2009-07-14 | |||||||||||
Sponsor Name:Santhera Pharmaceuticals (Switzerland) Limited | |||||||||||||
Full Title: A Phase III Double-Blind, Randomised, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Idebenone in 10 – 18 Year Old Patients with Duchenne Muscular Dystrophy | |||||||||||||
Medical condition: Duchenne Muscular Dystrophy | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) FR (Completed) NL (Completed) SE (Completed) AT (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003441-38 | Sponsor Protocol Number: 1042-TSC-3001 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Marinus Pharmaceuticals Inc. | |||||||||||||
Full Title: A Phase 3, Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults with Tuberous Sclerosis Complex (TSC)-related Epilepsy (TrustTSC) | |||||||||||||
Medical condition: Tuberous Sclerosis Complex (TSC)-related epilepsy | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DE (Completed) ES (Completed) IT (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-001109-26 | Sponsor Protocol Number: PS1/001/07 | Start Date*: 2010-11-04 |
Sponsor Name:Oxford BioMedica (UK) Ltd | ||
Full Title: A phase I/II study of the safety, efficacy and dose evaluation of ProSavin®, administered using stereotactic injection to the striatum of patients with bilateral, idiopathic Parkinson’s disease | ||
Medical condition: Patients with bilateral, idiopathic Parkinson's Disease | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-003426-89 | Sponsor Protocol Number: E2020-J081-345 | Start Date*: 2018-10-18 |
Sponsor Name:Eisai Co., Ltd. (Japan) | ||
Full Title: A Double-blind, Placebo-controlled Comparative Study and Open-label Extension Study to Confirm the Efficacy and Safety of E2020 in Subjects With Down Syndrome Having Regression Symptoms and Disable... | ||
Medical condition: Down syndrome, regression symptoms and disabled activities of daily living | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2010-019035-35 | Sponsor Protocol Number: A0081194 | Start Date*: 2011-02-21 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER TRIAL OF PREGABALIN CONTROLLED RELEASE FORMULATION AS ADJUNCTIVE THERAPY IN ADULTS WITH PARTIAL ONSET SEIZURES - PROTOCO... | |||||||||||||
Medical condition: Adjunctive (add on) therapy for adult subjects with partial onset seizures with or without secondary generalization. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) HU (Completed) DE (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004277-27 | Sponsor Protocol Number: MT-1621-102 | Start Date*: 2019-07-16 |
Sponsor Name:Modis Therapeutics, Inc. | ||
Full Title: A Phase 2 open-label study of continuation treatment with combination pyrimidine nucleos(t)ides in patients with thymidine kinase 2 deficiency (TK2) | ||
Medical condition: Thymidine kinase 2 deficiency | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2021-001294-23 | Sponsor Protocol Number: 232SM303 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Biogen Idec Research Limited | |||||||||||||
Full Title: A Phase 3b Study to Evaluate Higher Dose Nusinersen (BIIB058) in Patients With Spinal Muscular Atrophy Previously Treated With Risdiplam | |||||||||||||
Medical condition: Muscular Atrophy, Spinal | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) IT (Trial now transitioned) ES (Prematurely Ended) DE (Ongoing) PL (Completed) HU (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000222-19 | Sponsor Protocol Number: H2020-PHC-18-2015-667224 | Start Date*: 2017-08-02 | ||||||||||||||||
Sponsor Name:University Hospital Tuebingen | ||||||||||||||||||
Full Title: Effect of ALlopurinol in addition to hypothermia for hypoxic-ischemic Brain Injury on Neurocognitive Outcome – a blinded randomized placebo-controlled parallel group multicenter trial for superiori... | ||||||||||||||||||
Medical condition: Perinatal Asphyxia, hypoxic-ischemic brain injury | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Preterm newborn infants, Newborns, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Trial now transitioned) NL (Trial now transitioned) NO (Trial now transitioned) ES (Ongoing) FI (Trial now transitioned) EE (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) PT (Prematurely Ended) IT (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001403-23 | Sponsor Protocol Number: M15-535 | Start Date*: 2017-02-22 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: An Open-label, Randomized 12 Week Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects with ... | |||||||||||||
Medical condition: Dyskinesia in advanced Parkinson's disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) SK (Completed) GR (Completed) ES (Completed) HU (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001294-84 | Sponsor Protocol Number: OPBGC&RS2011-004_CA2012 | Start Date*: 2012-09-03 | |||||||||||
Sponsor Name:EDISON PHARMACEUTICALS INC. | |||||||||||||
Full Title: Prospective open label trial to evaluate the maintenance of the efficacy and the long term safety of EPI-743 in children with Leigh Disease | |||||||||||||
Medical condition: Leigh Disease | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-000321-31 | Sponsor Protocol Number: rhLAMAN-09 | Start Date*: 2013-06-07 | |||||||||||
Sponsor Name:Chiesi Farmaceutici S.p.A. | |||||||||||||
Full Title: A multi-center, un-controlled, open-labeled trial of the long-term safety of Velmanase Alfa aftercare treatment of subjects with alpha-Mannosidosis whom previously participated in Velmanase Alfa - ... | |||||||||||||
Medical condition: Treatement of Alpha-Mannosidosis | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001589-25 | Sponsor Protocol Number: BN29854 | Start Date*: 2015-11-19 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: Multicenter, open-label, single-arm study to evaluate long term safety, tolerability, and effectiveness of 10mg/kg BID olesoxime in patients with Spinal Muscular Atrophy | |||||||||||||
Medical condition: Spinal Muscular Atrophy | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IT (Completed) DE (Completed) BE (Completed) NL (Completed) FR (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002548-15 | Sponsor Protocol Number: VTS301 | Start Date*: 2015-12-01 |
Sponsor Name:Vtesse LLC, a Mallinckrodt Pharmaceutical Company | ||
Full Title: A Phase 2b/3 Prospective, Randomized, Double-blind, Sham-controlled Trial of VTS-270 (2-hydroxypropyl-β-cyclodextrin) in Subjects with Neurologic Manifestations of Niemann-Pick Type C1 (NPC1) Disease | ||
Medical condition: Neurologic Manifestations of Niemann-Pick Type C1 (NPC1) Disease | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) ES (Prematurely Ended) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2018-004496-12 | Sponsor Protocol Number: 1042-PCDH19-3002 | Start Date*: 2019-09-26 | |||||||||||
Sponsor Name:Marinus Pharmaceuticals, Inc. | |||||||||||||
Full Title: A double-blind, randomized, placebo-controlled trial of adjunctive ganaxolone treatment in female children with protocadherin 19 (PCDH19)-related epilepsy followed by long-term open-label treatment | |||||||||||||
Medical condition: protocadherin 19 (PCDH19)-related epilepsy | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Female | ||||||||||||
Trial protocol: FR (Completed) NL (Prematurely Ended) PL (Completed) HU (Completed) GB (GB - no longer in EU/EEA) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
